Page last updated: 2024-11-13

atglistatin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

atglistatin: inhibits adipose triglyceride lipase; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

atglistatin : A biphenyl that is 1,1'-biphenyl substituted by (dimethylcarbamoyl)amino and dimethylamino groups at positions 3 and 4', respectively. It is a potent inhibitor of adipose triglyceride lipase activity (IC50 = 700nM). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID71699712
CHEMBL ID3823931
SCHEMBL ID15186954
MeSH IDM0590635

Synonyms (37)

Synonym
3-(4'-(dimethylamino)-[1,1'-biphenyl]-3-yl)-1,1-dimethylurea
S7364
atglistatin
HY-15859
sr-03000003442
SR-03000003442-1
SCHEMBL15186954
1469924-27-3
AC-35213
3-(4'-(dimethylamino)biphenyl-3-yl)-1,1-dimethylurea
CHEMBL3823931 ,
J-690187
2-[(n-benzyl-l-phenylalanyl)amino]-5-iodobenzoic acid
AKOS026750242
EX-A293
urea, n'-[4'-(dimethylamino)[1,1'-biphenyl]-3-yl]-n,n-dimethyl-
HMS3653A18
mfcd28009494
atglistatin, >=98% (hplc)
NCGC00371133-07
bdbm50185419
3-[4'-(dimethylamino)-biphenyl-3-yl]-1,1-dimethylurea
SW220102-1
FT-0700208
SY038696
3-[4 inverted exclamation mark -(dimethylamino)-biphenyl-3-yl]-1,1-dimethylurea
AWOPBSAJHCUSAS-UHFFFAOYSA-N
AS-16730
BCP27988
NCGC00371133-10
HMS3744A05
CCG-267281
A884474
3-[3-[4-(dimethylamino)phenyl]phenyl]-1,1-dimethylurea
1-[4'-(dimethylamino)-[1,1'-biphenyl]-3-yl]-3,3-dimethylurea
EN300-172737
Z1785637773

Research Excerpts

Overview

Atglistatin is a specific inhibitor of murine ATGL, which has proven useful for the validation of ATGL as a potential drug target.

ExcerptReferenceRelevance
"Atglistatin is a specific inhibitor of murine ATGL, which has proven useful for the validation of ATGL as a potential drug target."( Structure-activity relationship studies for the development of inhibitors of murine adipose triglyceride lipase (ATGL).
Breinbauer, R; Doler, C; Fuchs, E; Grabner, GF; Mayer, N; Melcher, MC; Migglautsch, AK; Romauch, M; Schweiger, M; Zechner, R; Zimmermann, R, 2020
)
1.28

Treatment

ExcerptReferenceRelevance
"Atglistatin treatment led to a dramatic reduction of these pro-fibrotic and pro-apoptotic processes."( Pharmacological inhibition of adipose tissue adipose triglyceride lipase by Atglistatin prevents catecholamine-induced myocardial damage.
Bartolomaeus, H; Beyhoff, N; Breinbauer, R; Foryst-Ludwig, A; Grabner, GF; Grune, J; Kershaw, EE; Kintscher, U; Klopfleisch, R; Luettges, K; Migglautsch, AK; Ritter, D; Rothe, M; Schupp, M; Smeir, E; Steinhoff, JS; Thiele, A; Wilck, N; Zechner, R, 2022
)
1.67

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency21.31740.01237.983543.2770AID1645841
GVesicular stomatitis virusPotency23.91850.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency21.31740.00108.379861.1304AID1645840
Interferon betaHomo sapiens (human)Potency23.91850.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency23.91850.01238.964839.8107AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency23.91850.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency23.91850.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Patatin-like phospholipase domain-containing protein 2Mus musculus (house mouse)IC50 (µMol)2.85000.70002.85005.0000AID1721334; AID1721336
Patatin-like phospholipase domain-containing protein 2Homo sapiens (human)IC50 (µMol)0.70000.70000.70000.7000AID1310988
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (56)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
lipid droplet fusionPatatin-like phospholipase domain-containing protein 2Homo sapiens (human)
diacylglycerol biosynthetic processPatatin-like phospholipase domain-containing protein 2Homo sapiens (human)
negative regulation of sequestering of triglyceridePatatin-like phospholipase domain-containing protein 2Homo sapiens (human)
positive regulation of triglyceride catabolic processPatatin-like phospholipase domain-containing protein 2Homo sapiens (human)
triglyceride catabolic processPatatin-like phospholipase domain-containing protein 2Homo sapiens (human)
lipid storagePatatin-like phospholipase domain-containing protein 2Homo sapiens (human)
intracellular triglyceride homeostasisPatatin-like phospholipase domain-containing protein 2Homo sapiens (human)
acylglycerol acyl-chain remodelingPatatin-like phospholipase domain-containing protein 2Homo sapiens (human)
retinol metabolic processPatatin-like phospholipase domain-containing protein 2Homo sapiens (human)
lipid droplet disassemblyPatatin-like phospholipase domain-containing protein 2Homo sapiens (human)
lipid homeostasisPatatin-like phospholipase domain-containing protein 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (25)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
lipoprotein lipase activityPatatin-like phospholipase domain-containing protein 2Homo sapiens (human)
phospholipase A2 activityPatatin-like phospholipase domain-containing protein 2Homo sapiens (human)
triglyceride lipase activityPatatin-like phospholipase domain-containing protein 2Homo sapiens (human)
protein bindingPatatin-like phospholipase domain-containing protein 2Homo sapiens (human)
acylglycerol O-acyltransferase activityPatatin-like phospholipase domain-containing protein 2Homo sapiens (human)
retinyl-palmitate esterase activityPatatin-like phospholipase domain-containing protein 2Homo sapiens (human)
mono-olein transacylation activityPatatin-like phospholipase domain-containing protein 2Homo sapiens (human)
diolein transacylation activityPatatin-like phospholipase domain-containing protein 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (25)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
lipid dropletPatatin-like phospholipase domain-containing protein 2Homo sapiens (human)
nucleoplasmPatatin-like phospholipase domain-containing protein 2Homo sapiens (human)
cytoplasmPatatin-like phospholipase domain-containing protein 2Homo sapiens (human)
endoplasmic reticulum lumenPatatin-like phospholipase domain-containing protein 2Homo sapiens (human)
endoplasmic reticulum membranePatatin-like phospholipase domain-containing protein 2Homo sapiens (human)
lipid dropletPatatin-like phospholipase domain-containing protein 2Homo sapiens (human)
cytosolPatatin-like phospholipase domain-containing protein 2Homo sapiens (human)
plasma membranePatatin-like phospholipase domain-containing protein 2Homo sapiens (human)
cytoplasmPatatin-like phospholipase domain-containing protein 2Homo sapiens (human)
membranePatatin-like phospholipase domain-containing protein 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (21)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1721334Inhibition of murine ATGL expressed in COS-7 cells2020Bioorganic & medicinal chemistry, 08-15, Volume: 28, Issue:16
Structure-activity relationship studies for the development of inhibitors of murine adipose triglyceride lipase (ATGL).
AID1310985Inhibition of ATGL in mouse 3T3L1 cells assessed as inhibition of isoproterenol-stimulated lipolysis by measuring reduction in non-esterified fatty acid release in media at 20 uM preincubated for 4 hrs followed by isoproterenol addition measured after 1 h2016European journal of medicinal chemistry, Aug-08, Volume: 118New Atglistatin closely related analogues: Synthesis and structure-activity relationship towards adipose triglyceride lipase inhibition.
AID1721340In vivo inhibition of ATGL in 12 hrs fasted mouse assessed as reduction in circulating fatty acid level at 200 uM administered via oral gavage measured after 8 hrs2020Bioorganic & medicinal chemistry, 08-15, Volume: 28, Issue:16
Structure-activity relationship studies for the development of inhibitors of murine adipose triglyceride lipase (ATGL).
AID1721341In vivo inhibition of ATGL in 12 hrs fasted mouse assessed as reduction in circulating glycerol level at 200 uM administered via oral gavage measured after 8 hrs2020Bioorganic & medicinal chemistry, 08-15, Volume: 28, Issue:16
Structure-activity relationship studies for the development of inhibitors of murine adipose triglyceride lipase (ATGL).
AID1721338In vivo inhibition of ATGL in ad libitum fed mouse assessed as reduction in circulating fatty acid level at 200 uM administered via oral gavage measured after 8 hrs2020Bioorganic & medicinal chemistry, 08-15, Volume: 28, Issue:16
Structure-activity relationship studies for the development of inhibitors of murine adipose triglyceride lipase (ATGL).
AID1310988Inhibition of ATGL (unknown origin) overexpressed in Escherichia coli XL-1 cells using [9,10-3H(N)]triolein as substrate incubated for 60 mins by liquid scintillation counting method2016European journal of medicinal chemistry, Aug-08, Volume: 118New Atglistatin closely related analogues: Synthesis and structure-activity relationship towards adipose triglyceride lipase inhibition.
AID1721336Inhibition of recombinant murine ATGL expressed in Escherichia coli XL-1 lysates2020Bioorganic & medicinal chemistry, 08-15, Volume: 28, Issue:16
Structure-activity relationship studies for the development of inhibitors of murine adipose triglyceride lipase (ATGL).
AID1721339In vivo inhibition of ATGL in ad libitum fed mouse assessed as reduction in circulating glycerol level at 200 uM administered via oral gavage measured after 8 hrs2020Bioorganic & medicinal chemistry, 08-15, Volume: 28, Issue:16
Structure-activity relationship studies for the development of inhibitors of murine adipose triglyceride lipase (ATGL).
AID1721343In vivo inhibition of ATGL in 12 hrs fasted mouse assessed as reduction in circulating TG level at 200 uM administered via oral gavage in presence of poloxamer measured after 8 hrs2020Bioorganic & medicinal chemistry, 08-15, Volume: 28, Issue:16
Structure-activity relationship studies for the development of inhibitors of murine adipose triglyceride lipase (ATGL).
AID1721342In vivo inhibition of ATGL in 12 hrs fasted mouse assessed as reduction in circulating triacylglycerol level at 200 uM administered via oral gavage measured after 8 hrs2020Bioorganic & medicinal chemistry, 08-15, Volume: 28, Issue:16
Structure-activity relationship studies for the development of inhibitors of murine adipose triglyceride lipase (ATGL).
AID1721337Inhibition of recombinant murine ATGL expressed in Escherichia coli XL-1 lysates at 200 uM relative to control2020Bioorganic & medicinal chemistry, 08-15, Volume: 28, Issue:16
Structure-activity relationship studies for the development of inhibitors of murine adipose triglyceride lipase (ATGL).
AID1721335Inhibition of murine ATGL expressed in COS-7 cells at 200 uM relative to control2020Bioorganic & medicinal chemistry, 08-15, Volume: 28, Issue:16
Structure-activity relationship studies for the development of inhibitors of murine adipose triglyceride lipase (ATGL).
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's12 (46.15)24.3611
2020's14 (53.85)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.02

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.02 (24.57)
Research Supply Index3.33 (2.92)
Research Growth Index4.68 (4.65)
Search Engine Demand Index39.34 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.02)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (3.85%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other25 (96.15%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]